Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 6Breast Neoplasms 5Lymphoma, Follicular 4Neuroblastoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Recurrence 2Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Breast Neoplasms, Male 2Warts 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Optic Nerve Glioma 1

Interventions

Vincristine 3Prednisone 3Doxorubicin 3Cyclophosphamide 3Rituximab 2Etoposide 2vandetanib 1motesanib diphosphate 1liposomal doxorubicin 1denileukin diftitox 1Zidovudine 1Valganciclovir 1Tomography, X-Ray Computed 1Sirolimus 1Nivolumab 1Interferons 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Echocardiography 1EPOCH protocol 1Caves 1Brentuximab Vedotin 1Bortezomib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoproliferative Disorders × Granulocyte Colony-Stimulating Factor × Clear all
NCT00092222 2026-06-05

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡